PMID- 32899271
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 3
TI  - Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor.
LID - 10.3390/cancers12092501 [doi]
LID - 2501
AB  - BACKGROUND: We aimed to study the effect of socioeconomic differences and 
      molecular characteristics on survival in patients with young-onset pancreatic 
      neuroendocrine tumors (YOPNET) and typical-onset PNET (TOPNET). METHODS: We 
      identified the patients with YOPNET (<50 years) and TOPNET (>/=50 years) who 
      underwent definitive surgery diagnosed between 2004 and 2016 using the National 
      Cancer Database. We evaluated overall survival (OS) using the Kaplan-Meier and 
      Cox regression methods before and after propensity score matching. A publicly 
      available genomic dataset was used to compare mutation frequencies among the two 
      groups. RESULTS: A total of 6259 patients with PNET were included, of which 27% 
      were YOPNET. Patients with YOPNET were more likely to be Black, Hispanic, female, 
      and have private insurance versus patients with TOPNET (all p < 0.001). Patients 
      with YOPNET had a lower comorbidity score, but higher stage and tumor size (all p 
      < 0.001). YOPNET was associated with a greater improved OS than TOPNET before and 
      after propensity score matching (p < 0.001). On multivariable analysis, this 
      survival difference persisted for YOPNET as an independent prognostic factor 
      (unmatched p = 0.008; matched p = 0.01). For genomic analysis, patients with 
      YOPNET had a lower rate of multiple endocrine neoplasia type-1 (MEN-1) mutation 
      than patients with TOPNET (26% vs. 56%, p < 0.001). CONCLUSIONS: YOPNET 
      represents a disease with distinct clinical features. Patients with YOPNET who 
      underwent definitive surgery had better OS than patients with TOPNET despite 
      having higher stage and tumor size. YOPNET also had lower rate of MEN-1 mutation.
FAU - Goksu, Suleyman Yasin
AU  - Goksu SY
AUID- ORCID: 0000-0001-9453-342X
AD  - Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
FAU - Ozer, Muhammet
AU  - Ozer M
AD  - Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
AD  - Department of Internal Medicine, Capital Health Regional Medical Center, Trenton, 
      NJ 08638, USA.
FAU - Kazmi, Syed Mohammad Ali
AU  - Kazmi SMA
AD  - Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
FAU - Sanford, Nina Niu
AU  - Sanford NN
AD  - Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
FAU - Aguilera, Todd A
AU  - Aguilera TA
AD  - Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
FAU - Ahn, Chul
AU  - Ahn C
AD  - Department of Population and Data Sciences, UT Southwestern Medical Center, 
      Dallas, TX 75390, USA.
FAU - Hsiehchen, David
AU  - Hsiehchen D
AD  - Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
FAU - Sanjeevaiah, Aravind
AU  - Sanjeevaiah A
AD  - Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
FAU - Khosama, Leticia
AU  - Khosama L
AD  - Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
FAU - Bleeker, Jonathan
AU  - Bleeker J
AD  - Division of Hematology and Oncology, Sanford Medical Center, Sioux Falls, SD 
      57117, USA.
FAU - Atiq, Muslim
AU  - Atiq M
AD  - Division of Gastroenterology and Hepatology, Sanford Medical Center, Sioux Falls, 
      SD 57117, USA.
FAU - Beg, Muhammad Shaalan
AU  - Beg MS
AD  - Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 
      75390, USA.
LA  - eng
GR  - UL1TR001105/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200903
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7563582
OTO - NOTNLM
OT  - age of onset
OT  - database
OT  - multiple endocrine neoplasia
OT  - mutation
OT  - neuroendocrine tumors
OT  - pancreas
OT  - propensity score
OT  - young adult
COIS- The authors declare no conflict of interest.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
PMCR- 2020/09/03
CRDT- 2020/09/09 01:03
PHST- 2020/08/04 00:00 [received]
PHST- 2020/08/27 00:00 [revised]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/09/09 01:03 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
PHST- 2020/09/03 00:00 [pmc-release]
AID - cancers12092501 [pii]
AID - cancers-12-02501 [pii]
AID - 10.3390/cancers12092501 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Sep 3;12(9):2501. doi: 10.3390/cancers12092501.